Tarsier Pharma Valuation Multiples

Discover revenue and EBITDA valuation multiples for Tarsier Pharma.

Tarsier Pharma Overview

About Tarsier Pharma

Tarsier Pharma Ltd is a late clinical stage biopharmaceutical company, focused on the development and commercialization of novel pharmaceutical therapies to address unmet needs in ocular diseases with underlying inflammatory pathologies. Its dazdotuftide platform technology is a bio-inspired immunomodulator designed to treat blinding inflammatory ocular diseases, and is currently being developed as both eye drops and intravitreal injections. The company's Product Candidate Pipeline includes TRS01 and TRS02.


Founded

2016

HQ

Israel

Employees

7

Financials (Last FY)

Revenue: -
Net Income: -

Market Cap

-

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Tarsier Pharma Stock Performance

Tarsier Pharma has current market cap of -.

Market CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
------

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Tarsier Pharma Valuation Multiples

Tarsier Pharma Financial Valuation Multiples

As of November 19, 2026, Tarsier Pharma has market cap of -.

LTMLast FY202320242025202620272028

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Tarsier Pharma Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Valuation Multiples Across 230+ Verticals

Tarsier Pharma Competitors

Tarsier Pharma competitors include Eli Lilly, Johnson & Johnson, AbbVie, Roche, Merck, Novartis, AstraZeneca, Amgen, Gilead Sciences and Novo Nordisk.

Most Tarsier Pharma public comparables operate across Biopharmaceuticals and BioTech.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
Eli Lilly$65B$28B19.6x14.5x46.0x30.5x
Johnson & Johnson$94B$40B7.3x6.8x17.1x18.5x
AbbVie$61B$17B9.4x8.6x33.2x18.2x
Roche$75B$26B5.5x5.4x16.2x13.7x
Merck$65B$28B5.9x5.7x13.7x22.2x
Novartis$57B$22B5.9x5.9x15.3x14.3x
AstraZeneca$59B$19B5.3x5.0x16.1x13.8x
Amgen$37B$17B7.6x7.2x16.7x15.9x

This data is available for Pro users. Sign up to see all Tarsier Pharma competitors and their valuation data.

Start Free Trial

Tarsier Pharma VC Funding History

Before going public, Tarsier Pharma raised $3M in total equity funding, across 1 round.

Last private valuation of Tarsier Pharma was $16M, after raising $3M in September 2018 from Sun Pharma.


Tarsier Pharma Funding Rounds

DateStageInvestorsRaisedValuationRev. MultipleDeal Summary
Sep-18Strategic investmentSun Pharma$3M$16MSun Pharmaceutical Industries, India's largest drugmaker, agreed in September 2018 to acquire an 18.75% stake in Tarsius Pharma, an Israeli ophthalmology drug developer, for USD 3 million (about Rs 21.5 crore) in cash. Sun Pharma said in a stock exchange disclosure that the investment needed no regulatory approvals, would be completed by 15 September 2018 and would be made through a wholly owned subsidiary. The price implies a value of about USD 16 million for the whole company. The stake added to Sun Pharma's earlier minority investments in overseas drug developers, including a 15.9% stake in Krystal Biotech for USD 7 million in 2017, and to its presence in Israel, where it had taken control of Taro Pharmaceutical Industries in 2010. Ophthalmology accounted for about 2% of Sun Pharma's revenue in the year to March 2018. Tarsius Pharma was founded in February 2016 as an early-stage research and development company working on drug candidates for inflammatory eye diseases. The company later changed its name to Tarsier Pharma.

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Tarsier Pharma

When was Tarsier Pharma founded?Tarsier Pharma was founded in 2016.
Where is Tarsier Pharma headquartered?Tarsier Pharma is headquartered in Israel.
How many employees does Tarsier Pharma have?As of today, Tarsier Pharma has over 7 employees.
Is Tarsier Pharma publicly listed?Yes, Tarsier Pharma is a public company listed on NYSE.
What is the stock symbol of Tarsier Pharma?Tarsier Pharma trades under TARX ticker.
When did Tarsier Pharma go public?Tarsier Pharma went public in 2050.
Who are competitors of Tarsier Pharma?Tarsier Pharma main competitors include Eli Lilly, Johnson & Johnson, AbbVie, Roche, Merck, Novartis, AstraZeneca, Amgen, Gilead Sciences, Novo Nordisk.
Is Tarsier Pharma profitable?No, Tarsier Pharma is not profitable.
How many companies Tarsier Pharma has acquired to date?Tarsier Pharma hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Tarsier Pharma has invested to date?Tarsier Pharma hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Tarsier Pharma

Lists including Tarsier Pharma

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial